Lixte Biotechnology (LIXT) Stock Price, News & Analysis

Company Overview

LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

Key Stats

• Today's Range: $1.34 to $1.37
• 50-Day Range: $1.10 to $1.49
• 52-Week Range: $1.02 to $3.50
• Volume: 610 shs
• Average Volume: 185,837 shs
• Market Capitalization: $3.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

LIXT Stock Analysis - Frequently Asked Questions

How have LIXT shares performed this year?

Lixte Biotechnology's stock was trading at $2.03 at the beginning of 2025. Since then, LIXT stock has decreased by 33.7% and is now trading at $1.3450.
View the best growth stocks for 2025 here.

How were Lixte Biotechnology's earnings last quarter?

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) posted its quarterly earnings results on Monday, May, 12th. The company reported ($0.29) earnings per share for the quarter.

When did Lixte Biotechnology's stock split?

Lixte Biotechnology's stock reverse split on Monday, June 5th 2023. The 1-10 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Lixte Biotechnology IPO?

Lixte Biotechnology (LIXT) raised $7 million in an IPO on Wednesday, November 25th 2020. The company issued 1,500,000 shares at $4.75 per share. WestPark Capital and WallachBeth Capital served as the underwriters for the IPO.

Who are Lixte Biotechnology's major shareholders?

Top institutional shareholders of Lixte Biotechnology include FNY Investment Advisers LLC (3.40%). Insiders that own company stock include Rene Bernards, Der Baan Bastiaan Jeroen Van, Eric Forman and Regina Brown.
View institutional ownership trends.

How do I buy shares of Lixte Biotechnology?

Shares of LIXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lixte Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lixte Biotechnology investors own include Predictive Oncology (POAI), Sangamo Therapeutics (SGMO), Ford Motor (F), Insulet (PODD), Energy Select Sector SPDR Fund (XLE), Zomedica (ZOM) and Abbott Laboratories (ABT).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 6/06/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LIXT
• CIK: 1335105
• Web: www.lixte.com
• Phone: (631) 830-7092
• Fax: 631-982-5050
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$5.09 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -5,562.77%
• Return on Assets: -130.48%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.13
• Quick Ratio: 5.13

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.22 per share
• Price / Book: 6.27

Miscellaneous

• Outstanding Shares: 2,684,000
• Free Float: 1,916,000
• Market Cap: $3.70 million
• Optionable: Not Optionable
• Beta: 0.37